First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-...
SUZHOU, China, Feb. 27, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III …